CCL25 and neoplasm: Tumor cells-expressing CCR9 have competitive advantages, since engagement of the CCL25 ligand enhances cell survival and provides resistance to apoptosis via the phosphatidylinositide 3-kinase/Akt pathway on several solid tumors (20, 21, 24–30); it activates the JNK1 antiapoptotic pathway in leukemic cells (31) and participates in Notch1-mediated cell proliferation (19).